[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Pages 10675-10676]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-4212]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Registration

    By Notice dated October 1, 2004, and published in the Federal 
Register on October 29, 2004, (69 FR 63178), Cambrex North Brunswick 
Inc., Technology Center of New Jersey, 661 Highway One, North 
Brunswick, New Jersey 08902, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
N-Ethylamphetamine (1475)..................  I
Tetrahydrocannabinols (7370)...............  I

[[Page 10676]]

 
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
4-Methoxyamphetamine (7411)................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Methadone Intermediate (9254)..............  II
Morphine (9300)............................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cambrex North Brunswick, Inc., Technology Centre of New Jersey to 
manufacture the listed basic classes of controlled substances is 
consistent with the public interest at this time. DEA has investigated 
Cambrex North Brunswick, Inc., Technology Centre of New Jersey to 
ensure that the company's registration is consistent with the public 
interest. The investigation has included inspection and testing of the 
company's physical security systems, verification of the company's 
compliance with state and local laws, and a review of the company's 
background and history. Therefore, pursuant to 21 U.S.C. 823, and in 
accordance with 21 CFR 1301.33, the above named company is granted 
registration as a bulk manufacturer of the basic classes of controlled 
substances listed.

    Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 05-4212 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P